| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2006;81:562-567
© 2006 The Society of Thoracic Surgeons
a Centro Cardiologico Monzino IRCCS, University of Milan, Milan, Italy
b Institute of Cardiology, University of Milan, Milan, Italy
c Department of Pharmacological Sciences, University of Milan, Milan, Italy
d Department of Medical Chemistry, Biochemistry, and Biotechnology, University of Milan, Milan, Italy
e Center for Cardiopulmonary Pharmacology, University of Milan, Milan, Italy
Accepted for publication August 18, 2005.
* Address correspondence to Dr Parolari, Centro Cardiologico Monzino IRCCS, Via Carlo Parea 4, 20138 Milan, Italy (Email: aparolari{at}ccfm.it).
 |
Abstract |
|---|
 Top Abstract IntroductionPatients and MethodsResultsCommentReferences |
|---|
-III is a new marker reflecting oxidative stress; it has emerged as the most reliable marker of oxidative stress status in vivo. This study was designed to ascertain whether OPCAB compared with CABG represents a surgical strategy that avoids oxidative stress. To this end urinary isoprostanes and other established oxidative stress markers were measured during the first 24 hours after CABG and OPCAB.
METHODS: Fifty low-risk coronary patients were randomly assigned to CABG or OPCAB. Urinary isoprostane iPF2-III levels, plasma levels of free malondialdehyde, and total antioxidant status were measured before, during, and up to 24 hours after surgery.
RESULTS: In OPCAB iPF2-III excretion remained unchanged throughout the study. As expected, in CABG iPF2-III levels significantly increased during surgery and returned at baseline 24 hours later. Free malondialdehyde behaved similarly, with no change in OPCAB and sharp increases during CABG. Conversely, total antioxidant status showed a sharp drop during CABG, followed by a slow recovery, whereas a significantly lower drop occurred in OPCAB.
CONCLUSIONS: In this randomized study in low-risk coronary patients, OPCAB revealed less perioperative oxidative stress, as reflected by lack of excretion of iPF2-III in urine, by lack of increase of plasma free malondialdehyde, and by lower decreases in plasma total antioxidant status.
|
Introduction |
|---|
|
TopAbstractIntroductionPatients and MethodsResultsCommentReferences |
|---|
The avoidance of cardiopulmonary bypass (CPB), as well as of heart and lung ischemia-reperfusion, has been proposed to reduce the postoperative systemic inflammatory response in off-pump coronary artery bypass grafting (OPCAB). In fact, OPCAB is associated with a somehow lower degree of systemic inflammatory and oxidative response than conventional CABG during the intraoperative period and the very early hours after surgery [1, 5, 7, 8].
The F2 isoprostanes are a family of free radical catalyzed prostaglandin F2 isomers that are formed in situ from the fatty acid backbone esterified in membrane phospholipids. They are released in response to cellular activation and have been detected in human plasma and urine [9, 10]. Increased excretion of F2 isoprostanes in urine has been found in association with advanced age [11], chronic obstructive pulmonary disease [12], cigarette smoking [13], and hypercholesterolemia [14]. Due to their mechanism of formation, specific structural features, and chemical stability, they are considered a reliable index of oxidant stress and ensuing lipid peroxidation in vivo [15]. An increase in the urinary excretion of F2 isoprostanes has been previously reported in CABG [16], but we have found no information on isoprostane excretion available in patients undergoing OPCAB.
The present study tests the hypothesis that the increases in oxidative markers occurring during CABG are prevented in patients undergoing OPCAB. To this end we assessed the in vivo secretion of urinary excretion of F2 isoprostanes and the levels in plasma of some established markers of oxidative stress in patients undergoing CABG or OPCAB. In addition, the potential correlation of urinary excretion of F2 isoprostanes with some markers of oxidative stress in plasma was also evaluated.
|
Patients and Methods |
|---|
|
TopAbstractIntroductionPatients and MethodsResultsCommentReferences |
|---|
Patients were randomly assigned to CABG (n = 25) or OPCAB (n = 25). The same surgical and anesthetic team managed all patients. None of the patients were taking vitamins, dietary supplements, or drugs with established antioxidant properties during the study. Conventional therapy was allowed according to clinical judgment.
After internal mammary harvesting, heparin (300 IU/kg) was given and activated clotting time was kept 440 seconds or greater with additional heparin in both groups. Upon completion of distal and proximal coronary anastomoses, heparin was antagonized with protamine sulfate at a 1:1 ratio.
CABG
A nonpulsatile roller pump and hollow-fiber oxygenators were used. Cardiopulmonary bypass was initiated with cannulas placed in the ascending aorta and right atrium (two-stage venous cannula). Each operation was performed with tepid hypothermia (32–33°C) and hemodilution. During CPB, blood flow was maintained at 2.4 L · min · m2. Myocardial protection was achieved by the administration of cool, antegrade and retrograde multidose blood cardioplegia.
OPCAB
This procedure was performed by a midline sternotomy with the same heparinization protocol as described above. Mechanical stability of the coronary arteriotomy area was achieved with the Octopus IV system (Medtronic Inc, Minneapolis, MN) and a soft plastic coronary flow-shunt was always passed into the coronary arteriotomy to reduce myocardial ischemia and to improve visualization of the anastomosis field. The hemodynamic management of patients during distal coronary anastomosis consisted mainly in the careful and progressive elevation of the heart with tissue slices, associated with substantial volume administration to allow the heart to adapt to the new positioning and to avoid major hemodynamic derangements or need of inotropic drug administration.
Urine Sampling
An overnight urine collection the night before (pre), 4 to 6 hours after surgery start (during), and an overnight urine collection 24 hours after surgery (after) was carried out. The antioxidant 4-hydroxy-tempo (1 mmol/L; Sigma Chemical Co, St Louis, MO) was added to urine and samples stored at -80°C until analyzed.
Blood Sampling
Blood samples were collected at 7 time-points, from a catheter positioned in the radial artery, in tubes containing ethylenediaminetetraacetic acid (9.3 mM; Vacutainer Systems, Becton Dickinson, Rutherford, NY) as anticoagulant: before induction of anesthesia (t0, pre), after sternotomy (t1), 30 minutes after aortic cross-clamp in CABG and 30 minutes after the start of the first distal anastomosis in OPCAB (t2), after protamine administration (t3), at the end of surgery (t4, about 1.5 hours from t2), 4 hours after the arrival to the intensive care unit (t5), and 24 hours after surgery (t6). After blood centrifugation, plasma was removed and stored at –80°C until analyzed.
Isoprostane Determination
Urinary isoprostane iPF2-III was purified using a double extraction protocol followed by quantification using an enzyme-immunoassay (Cayman Chemical Co, Ann Arbor, MI – SPI-BIO, Saclay, France), according to Wang and colleagues [[11], with modification, as previously described [17]. A 20,000 dpm of [3H]-PGF2 was added as internal standard to 2 mL of urine and results were corrected for the recovery and expressed as picogram per milligram of creatinine. Only free (not esterified in phospholipids) isoprostanes can be detected.
Assay of Free Plasma Malondialdehyde (MDA)
Free plasma MDA levels were assessed, after organic extraction, with gas chromatography-mass spectrometry (GC-MS) as previously described [18]. Synthesized dideuterated-MDA was added as internal standard. The GC-MS analyses were carried out on a Hewlett-Packard 5890 gas chromatograph (HP Company, Palo Alto, CA) equipped with an HP-5 fuse silica capillary column (25 m, 0.32 mm id, 0.25 mm film thickness) and coupled to a 5988A mass spectrometer.
Assay of Individual Antioxidant Status (IAS)
Plasma IAS was measured by a commercially available spectrophotometric assay (OXY-Adsorbent Test, Diacron International, Grosseto, Italy). Plasma samples were submitted to massive oxidative stress with hypochlorous acid and IAS values determined by reading the absorbance at 505 nm.
Statistical Analysis
Normally distributed data are reported as means ± 1 standard deviation; data that were not normally distributed are reported as median and interquartile range (IQR) between brackets. Clinical variables of the patients were compared with two sample t-tests, 
2, or Fisher's exact tests when indicated. Values represented in time course charts are the mean differences (delta ± standard error of the mean) between each time point value and that measured at baseline.
In order to adjust for potential confounding factors (ie, age, gender, EF, previous myocardial infarction, and number of bypass performed), general linear model analysis of covariance models were used for statistical analysis of time, group (CABG vs OPCAB), and interaction (time*group) effects in oxidative stress variables; in this case skewed variables (iPF2-III) were log-transformed before analysis. When time, group, or interaction effects were significant (p < 0.05), repeated measures ANCOVA with Bonferroni correction was used to establish significant (p < 0.05) point-by-point differences.
To compute within subjects' correlations we first subtracted individual patient means from all values. The resulting residuals were then analyzed by Spearman correlation. All analyses were performed by SAS statistical package v.8 (SAS Institute Inc, Cary, NC).
|
Results |
|---|
|
TopAbstractIntroductionPatients and MethodsResultsCommentReferences |
|---|
|
-III in urine was 98.5 (67.5–155.5 IQR) and 99.5 (56-128 IQR) pmol/mmol creatinine in patients undergoing OPCAB and CABG, respectively (Table 2). In patients undergoing OPCAB urinary iPF2-III, excretion did not change significantly during the study; on the other hand, a consistent increase in isoprostane excretion was detected in CABG patients during surgery (153 pmol/mmol creatinine, 112-257 IQR, p < 0.01 vs presurgery), levels returning to baseline 24 hours after surgery (Fig 1A, and Table 2). Similarly, no change in plasma free MDA levels were observed in OPCAB patients, whereas in CABG patients free MDA was significantly higher than baseline and than OPCAB patients from the time point 30 minutes after aortic cross-clamp application (t2) up to surgery end (t4), and peaking after protamine administration (t3) (Fig 1B, and Table 2). Total MDA levels in plasma behaved as free MDA (data not shown).
|
|
-III, free MDA, IAS) considered.
In CABG patients a positive (r = 0.48, p < 0.0001) correlation was found between the changes in urinary iPF2-III and plasma free MDA. In addition, changes in iPF2-III and in plasma free MDA negatively correlated with changes in IAS (r = -0.53, p < 0.0001 and r = -0.46, p < 0.0001, respectively).
|
Comment |
|---|
|
TopAbstractIntroductionPatients and MethodsResultsCommentReferences |
|---|
-III in urine and of free MDA in plasma, together with an only modest reduction of plasma total antioxidant status in OPCAB, suggests that the contribution of general surgical trauma to the oxidative stress is minimal and affects only the endogenous antioxidant defense mechanism without sensibly increasing the production of prooxidant species.
Altered levels of immunoreactive iPF2-III in urine were reported in the clinical setting of coronary reperfusion [15] and in a variety of syndromes putatively associated with oxidant stress in vivo [16]. Moreover, isoprostanes are known to have biological effects in vitro through membrane receptors for prostanoids [19, 20] and may therefore be considered themselves as mediators of oxidative stress.
Our study does not answer the question of which cells or tissues, subjected to oxidant stress, contribute to the increased isoprostanes excretion and MDA formation detected during surgery in CABG patients. One likely source might be blood cells stressed when circulating through the heart-lung machine. Indeed, activation of granulocytes and subsequent release of oxygen-derived free radicals and granular enzymes are well-recognized during cardiac surgery with the use of CPB. Possible sites of leukocyte activation might be the coagulation and fibrinolytic cascades as well as complement activation, likely through the alternative pathway (eg, through blood-circuit contact) [3, 21]. Activated platelets may represent a direct source of isoprostanes as these cells might be significantly triggered by contact activation with the material surface of the heart-lung machine and are able to synthesize isoprostanes in a cyclooxygenase-dependent fashion [22]. Nonetheless, activated platelets may generate isoprostanes and thromboxane B2 in a molar ratio of approximately 1:1000 and it therefore seems difficult to link the increased concentrations of urinary iPF2-III simply with CPB-related platelet activation.
The sharp drop in IAS status detected in CABG patients may reflect an augmented utilization of plasma antioxidants, whereas the increases in iPF2-III and MDA suggest an enhanced oxidative stress. Thus, in CABG patients, free radical generation outweighs the endogenous defense mechanisms and may contribute to global myocardial reperfusion injury [23–25], whereas in OPCAB patients only a reduction in endogenous defense mechanisms was observed, as reflected by a relatively modest, but significant, reduction of IAS.
Thus, OPCAB minimizes intraoperative oxidative stress. Whether or not this protection is enough to prevent short-term or long-term clinical events is not addressed in this trial and requires further investigation. Up to the present time, multiple clinical studies have examined the issue whether or not off-pump coronary grafting is associated with lower mortality and morbidity rates without gaining a consensus [26–28]. In fact, no evidence coming from large, randomized controlled trials is available on these issues and all the available information comes mostly from observational, uncontrolled, nonrandomized clinical trials, which makes their generalization difficult [29].
In conclusion, our results indicate that patients undergoing OPCAB had only mild signs of oxidative stress compared with patients submitted to CABG. Further studies are needed to investigate whether this improved protection against oxidation will result in improved clinical outcomes.
|
References |
|---|
|
TopAbstractIntroductionPatients and MethodsResultsCommentReferences |
|---|
generation during coronary reperfusiona potential quantitative marker of oxidant stress in vivo. Circulation 1997;95:2492-2499.This article has been cited by other articles:
|
|
 |
|
  A. F. De Vecchi, F. Bamonti, C. Novembrino, S. Ippolito, L. Guerra, S. Lonati, S. Salini, C. S. Aman, E. Scurati-Manzoni, and G. Cighetti Free and total plasma malondialdehyde in chronic renal insufficiency and in dialysis patients Nephrol. Dial. Transplant., March 4, 2009; (2009) gfp102v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Moller, L. Penninga, J. Wetterslev, D. A. Steinbruchel, and C. Gluud Clinical outcomes in randomized trials of off- vs. on-pump coronary artery bypass surgery: systematic review with meta-analyses and trial sequential analyses Eur. Heart J., November 1, 2008; 29(21): 2601 - 2616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Mueed, T. Tazzeo, C. Liu, E. Pertens, Y. Zhang, I. Cybulski, L. Semelhago, J. Noora, A. Lamy, K. Teoh, et al. Isoprostanes constrict human radial artery by stimulation of thromboxane receptors, Ca2+ release, and RhoA activation J. Thorac. Cardiovasc. Surg., January 1, 2008; 135(1): 131 - 138. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
= coronary artery bypass grafting; 
= off-pump coronary artery bypass.)